In the worst quarter, we believe local companies will be able to make money on strong cost-saving capabilities.

But the lead will be short-lived as the Korean companies will be able to make panels at lower costs in their new factories after output increases in the second half of this year.

The government's tighter control over Chinese-bound investments will scarcely have any impact on flat panel makers as they did not bank any hope on an opening to save costs as other sectors did.

Dead money that springs to life will die again.

If a company doesn't use their time, money and manpower to tackle major commercial obstacles then the product will flop regardless of how much time, money and manpower is used. The successful brands are backed by teams that are knowledgeable about the industry and what potential problems may arise. These teams use what resources they have to make a favorable climate for their drug.

It's about money, permanent and significant damages. It's also about accountability on the part of the government and the media.